Aquestive Therapeutics (AQST) vs Collegium Pharmaceutical (COLL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aquestive Therapeutics (AQST) has outperformed Collegium Pharmaceutical (COLL) over the past year, losing 22.6% versus a loss of 34.3%. Over five years, AQST leads with a +19.4% price change compared with +4.5% for COLL. Collegium Pharmaceutical is the larger company by market cap ($715.9 million vs $581.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | COLL |
|---|---|---|
| Share price | $4.64 | $21.99 |
| Market cap | $581.75M | $715.90M |
| 1-day change | +0.32% | +0.27% |
| YTD return | -28.48% | -52.63% |
| 1-year return | -22.61% | -34.32% |
| 5-year return | +19.38% | +4.53% |
| P/E ratio (TTM) | — | 17.31 |
| Forward P/E | — | 3.31 |
| EPS (TTM) | $-0.66 | $1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.55 | $50.79 |
| 52-week low | $2.93 | $21.43 |
| Distance from 52-week high | -38.61% | -56.70% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +101.29% | +122.83% |
| Average volume | 2.66M | 748.29K |
| Shares outstanding | 125.51M | 32.56M |
| Employees | 147 | 423 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AQST has outperformed COLL by 11.7 percentage points over the past year.
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
AQST vs COLL FAQ
Which is bigger, Aquestive Therapeutics or Collegium Pharmaceutical?
Collegium Pharmaceutical (COLL) is larger, with a market capitalization of $715.90M compared with $581.75M for Aquestive Therapeutics (AQST).
Which stock has performed better over the past year, AQST or COLL?
AQST returned -22.61% over the past 12 months, compared with -34.32% for COLL (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Collegium Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.